Search Within

Martin Henner Voss

Formats
  1. Meeting Abstract (150)
  2. Journal Article (122)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (288)
  2. Genitourinary Oncology Service (288)
  3. Solid Tumor Oncology Division (288)
  4. Human Oncology and Pathogenesis Program (104)
  5. Weinberg Fellows (104)
  6. Surgery (103)

More Groups

People
  1. Robert Motzer (176)
  2. Abraham Hakimi (95)
  3. Darren Feldman (80)
  4. Chung-Han Lee (75)
  5. Maria Carlo (65)
  6. Ritesh Kotecha (63)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (116)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (120)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (18)
  6. Biomed Central Ltd (15)

More Publishers

Results (288)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
    Journal Article

    Gouda, M. A.; Voss, M. H.; Tawbi, H.; Gordon, M.; Tykodi, S. S.; Lam, E. T.; Vaishampayan, U.; Tannir, N. M.; Chaves, J.; Nikolinakos, P.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses
    Meeting Abstract

    Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study
    Meeting Abstract

    Dizman, N.; Doshi, S. D.; Knezevic, A.; Feinaj, A.; Sayegh, N.; Hobeika, C.; Alaghehbandan, R.; Rives, H.; Zengin, Z. B.; Braun, D. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes and targeted genomic analysis of renal cell carcinoma brain metastases treated with stereotactic radiosurgery
    Journal Article

    Ma, J.; del Balzo, L.; Walch, H.; Khaleel, S.; Knezevic, A.; Flynn, J.; Zhang, Z.; Eichholz, J.; Doshi, S. D.; Voss, M. H.; more...
    European Urology Oncology (2025)

    Fulltext@MSK | Save
  • Prospective study of patient, nursing, and oncology provider perspectives on telemedicine visits for renal cell carcinoma clinical trials
    Journal Article

    Doshi, S. D.; Knezevic, A.; Gonzalez, C.; Fischer, P.; Goodman, R.; Gornell, S.; Patel, S.; Puzio, C.; Ritea, A.; Lee, C. H.; more...
    Clinical Genitourinary Cancer (2025)

    Fulltext@MSK | Save
  • Management of kidney cancer relapse to adjuvant pembrolizumab: Early insights and questions for a newly emerging space
    Editorial

    Voss, M. H.; Motzer, R. J.
    European Urology (2024)

    Fulltext@MSK | Save
  • Real world data on treatment of chromophobe renal cell carcinoma
    Meeting Abstract

    Battle, D.; Griffith, M.; Msaouel, P.; Voss, M. H.; Staehler, M. D.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma
    Meeting Abstract

    Doshi, S. D.; Kuo, F.; Knezevic, A.; Kotecha, R. R.; Motzer, R. J.; Hakimi, A. A.; Voss, M. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study
    Meeting Abstract

    Voss, M. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save